Brought to you by 
Astra acquired worldwide rights to Allelix's ALX1-11
11 Nov 1999
Executive Summary
Astra acquired exclusive worldwide rights to Allelix's (CNS, hormone and gene-related diseases) ALX1-11, a recombinant human parathyroid hormone (PTH) for the treatment of osteoporosis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astra acquired worldwide rights to Allelix's ALX1-11
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice